New option opens for patients who have exhausted several therapies in their fight against relapsed or refractory multiple …
New option opens for patients who have exhausted several therapies in their fight against relapsed or refractory multiple …
Adding atezolizumab to FOLFOX chemotherapy after surgery boosts disease-free survival in patients with surgically resected mismatch repair deficient …
A phase 3 study reveals combining inavolisib with fulvestrant and palbociclib substantially delays progression and prolongs survival in …
Landmark ATOMIC trial shows combining immunotherapy and chemo improves outcomes for colon cancer patients with mismatch-repair deficiency
Triple-drug combination extending life for women with aggressive HR+/HER2− breast cancer
In late May 2025 a major funding round highlights how investors are backing clinical-stage pipelines together with AI …
FDA’s Oncologic Drugs Advisory Committee (ODAC) critiques a major lymphoma trial for having too few U.S. participants, warning …
Combination therapy delivers promising efficacy and manageable safety in PD-1 refractory head and neck squamous cell carcinoma
Oral brain-penetrant NLRP3 inhibitor and new collaborations place BioAge at center of metabolic aging drug development
Trial halt and valuation collapse trigger major workforce reduction at fibrosis-focused biotech
Already a subscriber? Log in